Oxford University Hospitals specialists have secured £520,000 from the National Institute for Health and Care Research’s Research for Patient Benefit programme for a national multicentre clinical trial.
The investigation, led by consultant haematologist Dr Nicola Curry and senior haemophilia physiotherapist Steph Taylor, will assess a treatment for ankle arthritis associated with haemophilia.
Its focus is intra-articular hyaluronic acid, a naturally occurring substance within joints that is sometimes described as liquid cartilage.
Researchers will examine whether injecting this substance into affected ankles can ease pain, enhance joint function and improve mobility in people with haemophilic arthropathy.
The trial has been designed with the involvement and strong backing of patients who have haemophilia.
Patients prompted the specialists to investigate improved ankle treatments in 2018, and the new funding will enable the work to proceed as a larger study across the UK.
Findings from a pilot study in 2023 indicated that hyaluronic acid may reduce pain and improve ankle function among this patient group.
The expanded, placebo-controlled trial seeks to establish whether those benefits can be demonstrated consistently and whether the treatment also improves quality of life.
